European Medicines Agency Guidance for applicants seeking scientific advice and protocol assistance

The European Medicines Agency Guidance for Scientific Advice and Protocol Assistance provides structured guidance for sponsors and applicants seeking scientific advice (SA) or protocol assistance (PA) on the design, conduct, and development of medicinal products, including clinical trials. This guidance helps applicants optimize study protocols, regulatory strategies, and development plans before submission to the EMA, improving the quality, efficiency, and regulatory compliance of trials conducted in the European Union.

Key features and content include: 

• Regulatory Alignment: Clarifies procedures for obtaining EMA scientific advice or protocol assistance to ensure compliance with EU regulatory expectations.
• Trial Design Optimisation: Supports sponsors in refining clinical study protocols, endpoints, and statistical plans based on regulatory feedback.
• Risk Mitigation: Early dialogue with EMA helps identify potential regulatory, methodological, or safety issues before study initiation.
• Efficient Development Planning: Encourages structured planning for clinical trials, including paediatric investigation plans (PIPs), adaptive designs, and multi-regional considerations.
• Enhanced Sponsor-Regulator Communication: Provides a framework for clear, pre-submission engagement with regulators to reduce review delays and improve trial approval success.